ACTC Achieves Clinical Milestone: Up again

Advanced Cell Technology Achieves Clinical Milestone Font size: A | A | A 8:30 AM ET 1/8/13 | BusinessWire Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, announced today that investigators for the Company's Phase I/II clinical trials for Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) have observed evidence of engraftment of the transplanted human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells and visual acuity gain in patients treated over the 18 months since the trials were first initiated. The Company believes this observation of engraftment and persistence is clinically important because engraftment of cells in the proper area, and recapitulation of normal RPE cell layer structure is important to the ultimate efficacy of the RPE cells in the treatments. Additionally, investigators have not observed any issues of safety relating to the transplanted human embryonic stem cell (hESC)-derived RPE cells in any of the 18 patients treated. The company believes this warrants early (though cautious) optimism as the company looks forward to initiating the second half of the three trials. "Now that we are at the halfway point in all three of our ongoing trials, we have had the opportunity to stop and assess not only the data relating to safety, but also to the activity of the transplanted RPE cells," said Gary Rabin, chairman and CEO. "In our first report of hESC-derived cells transplanted into patients, published in the Lancet, we reported no adverse safety signals and that both patients that had been treated by that point showed some signs of visual improvements. For both of those patients, those gains in visual acuity have persisted for nearly 18 months now. In addition, we have observed persisting engraftment of the transplanted RPE cells in our more recent SMD and dry AMD patients. This is the first time we have shown this in dry AMD patients, which we find particularly encouraging, given that dry AMD represents one of the largest unmet medical needs in the world." "We are optimistic about the prospects of our RPE cells ultimately impacting positively on various forms of macular degeneration," said Robert Lanza, M.D., ACT's chief scientific officer. "As we have added additional clinical trial sites, the pace of patient treatments has picked up. At the same time, we are extending our observations to a greater number of patients, as well as collecting data over extended periods of time after the surgery." Mr. Rabin will be providing an overview of the company's progress, including providing some representative examples of anatomical data of RPE engraftment in the trials, in his presentation on Tuesday, Jan. 8 at Biotech Showcase 2013 in San Francisco. Pictures of the engraftment will be included in Mr. Rabin's presentation, which will be posted to the Presentations section of the ACT site, and a link to a webcast of the presentation will be available on the Events section. Great news, should move up to 10 cents................................................ ......................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Great day for BTX and ACTC

BTX picked up 400 patents dealing with human embryonic stem cells from Geron. BTX was up 25 cents to close at $3.45. The volume was 268,062 shares. The three month avg. volume is 95,221 shares. BTX needs $500,000,000 [just a guess] to finish the trials on the acute spiral cord injuries. They have around $20 million. I think they will be taking donations....................................................................... ACTC up big to close at 0.0899 an huge volume of 73,331,184 shares. The three month avg. is 6.6 million shares. CEO Gary Rabin will present at Biotech Showcase, Jan. 8 in San Francisco.......................................................................... Geron was up 2 cents to close at $1.60 on only 877,078 shares. ........................ Good luck in this rigged casino,

BioTime done deal with Geron. ACTC up big again

What a great day! BioTime signs definitive agreement with Geron regarding stem cell assets. BTX up 10% and Geron up 2 cents. This is great news, the Phase 1 trial should start again. That's the one trying to repair acute spiral cord injuries, yea baby. So BioTime is now the future in bio-tech, you heard it here first...................... ............................................................................................................................................................................................................................................................................................................................................................ACTC up big again over 9 cents. No news, thinking it's coming very soon, maybe Tuesday Jan. 8th the CEO is speaking.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Good luck in this rigged casino,

ACTC up 31% YEA BABY

ACTC up 31% on heavy volume to close at 0.0799. Looked for news, nothing great. Thinking maybe more good results on Phase 1/2 trials, are coming out soon. ACTC volume was 25.5 million shares, the three month avg. 6.4 million shares.........Geron was up 5 cents to close at $1.58 on only 756,396 shares. No news, only have a few shares like, so with my luck Geron should hit $5 this year..... Good luck in this rigged casino,

Still Waiting

Fiscal cliff, Phase 2 results, and partners. No good news today.............. Geron down 1 cent to $1.59 on light volume of 771,484. The three month avg. volume is 1.1 million ,,,,,,,,ACTC 0.0615 up a little on 8.6 million shares. The three month avg. volume is 6.2 million shares. ...Good luck in this rigged casino,

Good News for ACTC

MARLBOROUGH, Mass., Dec 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the "10 Ideas That Will Shape The Year" in the 'Christmas and New Year Special' issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world. The list includes innovations in different scientific areas such as health and medicine, climate change, technology and others. ACT's platelet program aims to provide a renewable, donorless source of blood platelets to people in need of platelet transfusions. "Human iPS cells are a game-changer in medicine," said Robert Lanza, M.D., chief scientific officer of ACT. "They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don't contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013." ACT plans to compare normal and iPS cell-derived platelets in eight healthy volunteers and analyze recovery and survival. Additionally, normal platelets will be compared to human embryonic stem cell-derived platelet cells. "We appreciate this recognition from the New Scientist," commended Gary Rabin, chairman and CEO. "It speaks to the growing importance of the stem cell and regenerative medicine sector." ACTC is up just a little............................................................... .................................................................................................................................................................................Good luck in this rigged casino,

Waiting

It's just a waiting game, the fiscal cliff, the Phase 1/2 results and year end bouses. ......................................................................................................................................................................................................................................................................Geron closed at $1.60 up 2 cents. Volume was only 822,874 shares. The three month avg. is 1.2 million shares. Some people think they will get a buy out. What is there then to buy?........................................................................... ...............................................................................................................................................................................ACTC under 6 cents again at 0.0595 on 13.6 million shares. The three month avg. is 6.5 million shares.................................................................... ......................................................................................................................................................................................BTX closed at $3.50 I still think if they get Geron's stem cell property. They will be the furture in bio tech. They will need $500,0000,0000 to finish the trials.. ......................................................................................................................................................................................................................................................................AAPL closed at $526.31 down $7.59 on only 15.7 million shares. The three month avg. volume is 21.8 million shares. Hoping for a run the $625 in Jan 2013. ................. ...................................................................................................................................................................................Good luck in this rigged casino,